Log in Free sign up

Solid Biosciences (SLDB) News and press releases

News

From Benzinga Pro

What 4 Analyst Ratings Have To Say About Solid Biosciences

Analyst Ratings

Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Piper Sandler Maintains Neutral on Solid Biosciences, Lowers Price Target to $2

News, Price Target, Analyst Ratings

Piper Sandler analyst Allison Bratzel maintains Solid Biosciences (NASDAQ:SLDB) with a Neutral and lowers the price target from $5 to $2.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 807 companies reached new 52-week lows.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

During Wednesday's trading, 435 companies set new 52-week lows.

Looking Into Solid Biosciences's Return On Capital Employed

Solid Biosciences (NASDAQ:SLDB) brought in sales totaling $1.93 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 36.1%, resulting in a loss of $25.33 million.

Stocks That Hit 52-Week Lows On Friday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 213 companies hit new 52-week lows.

10 Biggest Price Target Changes For Thursday

Penny Stocks, Price Target, Pre-Market Outlook, Analyst Ratings

Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading.

Piper Sandler Maintains Neutral on Solid Biosciences, Lowers Price Target to $5

News, Price Target, Analyst Ratings

Piper Sandler analyst Allison Bratzel maintains Solid Biosciences (NASDAQ:SLDB) with a Neutral and lowers the price target from $6 to $5.

SVB Leerink Maintains Outperform on Solid Biosciences, Raises Price Target to $15

News, Price Target, Analyst Ratings

SVB Leerink analyst Joseph Schwartz maintains Solid Biosciences (NASDAQ:SLDB) with a Outperform and raises the price target from $12 to $15.

Chardan Capital Maintains Buy on Solid Biosciences, Lowers Price Target to $7

News, Price Target, Analyst Ratings

Chardan Capital analyst Geulah Livshits maintains Solid Biosciences (NASDAQ:SLDB) with a Buy and lowers the price target from $17 to $7.

62 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Tenon Medical, Inc. (NASDAQ: TNON) rose 350% to clsoe at $22.50 on Wednesday after the company priced its IPO at $5.00 per share.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Duchenne Player Solid Biosciences Realigns Pipeline Strategy, Cuts Staff By 35%

Biotech, Earnings, News, Penny Stocks, Guidance, Health Care, Movers, Trading Ideas, General

Solid Biosciences Inc (NASDAQ: SLDB) is shaving down its pipeline, updating its operations strategy to prioritize the advancement of AAV-mediated gene transfer therapies, SGT-001 and SGT-003.

Recap: Solid Biosciences Q1 Earnings

Solid Biosciences (NASDAQ:SLDB) reported its Q1 earnings results on Wednesday, April 27, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Biotech, Earnings, Large Cap, M&A, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, Movers, Trading Ideas, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Earnings Scheduled For April 27, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Deutsche Bank (NYSE:DB) is projected to report earnings for its first quarter.

Earnings Outlook For Solid Biosciences

Solid Biosciences (NASDAQ:SLDB) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Solid Biosciences will report an earnings per share (EPS) of $-0.18.

23 Stocks Moving in Thursday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers IZEA Worldwide, Inc. (NASDAQ: IZEA) rose 33.3% to $1.92 in pre-market trading after the company reported Q4 EPS results up from last year and better-than-expected sales results.

Solid Biosciences's Return On Capital Employed Insights

Benzinga Pro data, Solid Biosciences (NASDAQ:SLDB) reported Q4 sales of $3.15 million. Earnings fell to a loss of $18.61 million, resulting in a 3.49% decrease from last quarter.

Press releases

From Benzinga Pro

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy

Health Care, Press Releases

- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process - - Novel capsid development to

Solid Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and 2-Year Efficacy and Safety Data from the Ongoing Phase I/II IGNITE DMD Clinical Trial of SGT-001

Earnings, Analyst Ratings, Press Releases

- 2-year data from first three patients in the high dose (2E14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes compared with expected